# Novo real-world studies link Wegovy® 2.4 mg to reductions in liver enzymes, weight, and blood sugar in adults with MASH at The Liver Meeting® (AASLD) 2026

- Source: PR Newswire M&A
- Published: 2026-11-06T20:07:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/novo-real-world-studies-link-wegovy-2-4-mg-to-reductions-in-liver-enzymes-weight-and-blood-sugar-in-adults-with-mash-at-the-liver-meeting-aasld-2026--302932360.html
- Canonical: https://groundlevelnews.com/story/novo-real-world-studies-link-wegovy-2-4-mg-to-reductions-in-liver-enzy-24952b/

In a real-world study, semaglutide 2.4 mg once weekly injection was associated with a statistically significant mean weight loss from baseline, 18.9 lb (8.6 kg; ~8%), when compared to resmetirom at six months Semaglutide 2.4 mg was also associated with significantly greater reductions...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._